Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BB Biotech ( (CH:BION) ) has provided an announcement.
BB Biotech AG has released its interim report for the first nine months of 2025, revealing a significant profit increase to CHF 106 million, compared to CHF 16 million in the same period last year. The third quarter alone saw a profit of CHF 448 million, a notable turnaround from a loss of CHF 157 million in the previous year, reflecting positive share price developments in its portfolio companies.
The most recent analyst rating on (CH:BION) stock is a Buy with a CHF66.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.
More about BB Biotech
BB Biotech AG is an investment company based in Schaffhausen, Switzerland, and is listed on the Swiss and German stock exchanges. Since 1993, it has focused on investing in innovative drug development companies, primarily located in the USA and Western Europe. The company is recognized as a leading investor in this sector, with its investment strategy and decisions guided by a skilled board of directors and an experienced investment management team from Bellevue Asset Management AG.
Average Trading Volume: 94,300
Technical Sentiment Signal: Hold
Current Market Cap: CHF2.14B
Learn more about BION stock on TipRanks’ Stock Analysis page.